Gottlieb GS, Badiane NM, Hawes SE, Fortes L, Toure M, Ndour CT, Starling AK, Traore F, Sall F, Wong KG, Cherne SL, Anderson DJ, Dye SA, Smith RA, Mullins JI, Kiviat NB, Sow PS, University of Washington-Dakar HIV-2 Study Group (2009). Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 48(4), 476-83. (pubmed) (doi)
The efficacy of various antiretroviral (ARV) therapy regimens for human immunodeficiency virus type 2 (HIV-2) infection remains unclear. HIV-2 is intrinsically resistant to the nonnucleoside reverse-transcriptase inhibitors and to enfuvirtide and may also be less susceptible than HIV-1 to some protease inhibitors (PIs). However, the mutations in HIV-2 that confer ARV resistance are not well characterized.
Genbank accession numbers FJ812523-FJ812692 correspond to sequence generated in this study.
Analysis of polymorphic amino acids sites in RT and PR was performed using InSites. HIV-2 RT and PR consensus, HIV-2 ROD, and patients are shown. Polymorphic amino acid sites, their protein position, and their respective changes from the consensus are shown in columns. Unique (private) changes are shown in the right hand column.